(1R,2S,5S)-N-[1-(benzenesulfonylcarbamoyl)cyclopropyl]-3-[(2S)-2-[[(2S)-3,3-dimethyl-1-[methyl(thiophen-2-ylsulfonyl)amino]butan-2-yl]carbamoylamino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide | 877381-88-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1R,2S,5S)-N-[1-(benzenesulfonylcarbamoyl)cyclopropyl]-3-[(2S)-2-[[(2S)-3,3-dimethyl-1-[methyl(thiophen-2-ylsulfonyl)amino]butan-2-yl]carbamoylamino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
• CAS: 877381-88-9
• 化学式: C₃₆H₅₂N₆O₈S₃
• 分子量: 793.042
• InChiKey: RFCVDUJLRJOOHG-AYASFNNFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  53
• 可旋转键数：
  14
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  236
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• Method of treating interferon non-responders using HCV protease inhibitor
  申请人：Albrecht K. Janice

  公开号：US20070004635A1

  公开（公告）日：2007-01-04

  A method of treating, preventing or ameliorating one or more symptoms associated with hepatitis C virus (HCV) in a patient in whom either the HCV is of Genotype 1 and/or the patient was previously treated with interferon and the previous interferon therapy was ineffective to treat the one or more symptoms associated with HCV, comprising administering to such a patient an effective amount of at least one compound of formulae I-XXVI of which the following structural formula is exemplary or a pharmaceutically acceptable salt, solvate or ester thereof. Optional combined administration of said at least one compound with an interferon or pegylated interferon and/or ribaviron is also contemplated.